| Drug Name |
Tafluprost |
| Drug ID |
BADD_D02108 |
| Description |
A prostaglandin analogue ester prodrug used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. Chemically, tafluprost is a fluorinated analog of prostaglandin F2-alpha. Tafluprost was approved for use in the U.S. on February 10, 2012. |
| Indications and Usage |
Tafluprost is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. |
| Marketing Status |
approved |
| ATC Code |
S01EE05 |
| DrugBank ID |
DB08819
|
| KEGG ID |
D06274
|
| MeSH ID |
C485333
|
| PubChem ID |
9868491
|
| TTD Drug ID |
D04LCQ
|
| NDC Product Code |
82584-609; 61556-080; 65035-137; 54893-0021; 63190-0590; 76397-013; 65302-062; 68245-0012; 75872-0001; 66993-429; 0781-6184; 70390-0001; 17478-609 |
| UNII |
1O6WQ6T7G3
|
| Synonyms |
tafluprost | 1-methylethyl (5Z)-7-((1R,2R, 3R,5S)-2-((1E)-3,3-difluoro-4-phenoxy -1-butenyl)-3,5-dihydroxycyclopentyl)-5-heptenoate | AFP-168 |
